<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03583970</url>
  </required_header>
  <id_info>
    <org_study_id>PSS2017/LVADECMO-FRITZ/YB</org_study_id>
    <nct_id>NCT03583970</nct_id>
  </id_info>
  <brief_title>Veno-arterial Extracorporeal Membrane Oxygenation Prior to Left Ventricular Assist Device Implantation.</brief_title>
  <acronym>LVAD-ECMO</acronym>
  <official_title>Veno-arterial Extracorporeal Membrane Oxygenation Support Prior to Left Ventricular Assist Device Implantation : Initial Patients Characteristics and 6 Month Follow-up, a Retrospective Study (2013-2017) (LVAD-ECMO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiogenic shock is an uncommun pathology with a high mortatily rate around 45%. Veno
      arterial extracorporeal membrane oxygenation (VA-ECMO) is a temporary extracorporeal assist
      device which restore an adequate blood flow when a circulatory failure occures. VA-ECMO main
      indication is refractory cardiogenic shock whatever the etiology. Current medical care of
      terminal cardiac failure includes use of long-term mechanical circulatory support devices
      (MCSD) such as Left Ventricular Assist Device (LVAD). LVAD therapy may lead to heart
      transplant (bridge to transplantation), to recovery (bridge to recovery) or to permanent
      implantation (destination therapy). Few patients with refractory cardiogenic shock treated
      with VA-ECMO may secondarily need a long term MCSD with LVAD.

      LVAD long-term heart assist showed interesting survival rate when implantation occured (71%
      after 2 years follow-up and 45% after 4 years follow-up) out of acute heart failure
      situation. There are only few datas concerning LVAD implantion during refractory cardiogenic
      shock, with a mortality between 20 to 50% in different studies.

      In this way, in comparaison of current few datas on the subject of LVAD implantation under
      VA-ECMO, the investigators (15 french-speacking centers) would retrospectively describe a
      large population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>6-month hospital discharge after LVAD implantation</measure>
    <time_frame>6 month after LVAD implantation</time_frame>
    <description>6-month hospital discharge after LVAD implantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>up to six month after LVAD implantation</time_frame>
    <description>Six month mortality rate after LVAD implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU discharge</measure>
    <time_frame>up to six month after LVAD implantation</time_frame>
    <description>Days until ICU discharge after LVAD implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>up to six month after LVAD implantation</time_frame>
    <description>ADL and IADL scale</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hemodynamic Failure</measure>
    <time_frame>Before LVAD implantation - up to 28 day - up to 6 month</time_frame>
    <description>Amount of Norepinephrine infused</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiogenic failure</measure>
    <time_frame>Before LVAD implantation - up to 28 day - up to 6 month</time_frame>
    <description>Amount of inotrope infused</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardio-circulatory failure</measure>
    <time_frame>Before LVAD implantation - up to 28 day - up to 6 month</time_frame>
    <description>ECLS assistance</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal failure</measure>
    <time_frame>Before LVAD implantation - up to 28 day - up to 6 month</time_frame>
    <description>Worst KDIGO stage</description>
  </other_outcome>
  <other_outcome>
    <measure>Hepatic failure</measure>
    <time_frame>Before LVAD implantation - up to 28 day - up to 6 month</time_frame>
    <description>Worst values of PT/bilirubin/ AST and ALT</description>
  </other_outcome>
  <other_outcome>
    <measure>Thrombosis complication</measure>
    <time_frame>Before LVAD implantation - up to 28 day - up to 6 month</time_frame>
    <description>Thrombosis event</description>
  </other_outcome>
  <other_outcome>
    <measure>Haemorragic complication</measure>
    <time_frame>Before LVAD implantation - up to 28 day - up to 6 month</time_frame>
    <description>Haemorragic event</description>
  </other_outcome>
  <other_outcome>
    <measure>Respiratory failure</measure>
    <time_frame>Before LVAD implantation - up to 28 day - up to 6 month</time_frame>
    <description>Ventilation assistance</description>
  </other_outcome>
  <other_outcome>
    <measure>Neurological failure</measure>
    <time_frame>Before LVAD implantation - up to 28 day - up to 6 month</time_frame>
    <description>neurological sequelae</description>
  </other_outcome>
  <other_outcome>
    <measure>Infection complication</measure>
    <time_frame>Before LVAD implantation - up to 28 day - up to 6 month</time_frame>
    <description>documented infection</description>
  </other_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cardiogenic Shock</condition>
  <condition>Heart Failure</condition>
  <condition>Extracorporeal Membrane Oxygenation</condition>
  <condition>Left Ventricular Assist Device</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Left Ventricular Assist Device Implantation</intervention_name>
    <description>Veno-arterial extracorporeal membrane oxygenation prior to left ventricular assist device implantation : initial patients characteristics and 6 Month Follow-up</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients between 01.01.2013 and 31.12.2017 in the participating centers implanted with
        LVAD during VA-ECMO therapy for refractory cardiogenic shock.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Veno-arterial ExtraCorporeal Membrane Oxygenation prior to left ventricular assist
             device implantation.

          -  Veno-arterial ExtraCorporeal Membrane Oxygenation at the left ventricular assist
             device implantation operative time

        Exclusion Criteria:

          -  ExtraCorporeal Membrane Oxygenation weaving before left ventricular assist device
             implantation.

          -  Cardiac assist devices other than Veno-arterial ExtraCorporeal Membrane Oxygenation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Levy, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CHRU Nancy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline Fritz, MD</last_name>
    <phone>+3383157379</phone>
    <email>fritzcaro@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline FRITZ, MD</last_name>
      <phone>+33383157379</phone>
      <email>c.fritz@chru-nancy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Bruno LEVY, MD-PhD</last_name>
      <phone>+33383154469</phone>
      <email>b.levy@chru-nancy.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 6, 2018</study_first_submitted>
  <study_first_submitted_qc>June 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2018</study_first_posted>
  <last_update_submitted>July 16, 2018</last_update_submitted>
  <last_update_submitted_qc>July 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>Caroline FRITZ</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Left Ventricular Assist Device</keyword>
  <keyword>Extracorporeal Membrane Oxygenation</keyword>
  <keyword>Refractory Cardiogenic Shock</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Cardiovascular diseases</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Myocardial Ischemia</keyword>
  <keyword>Shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Shock, Cardiogenic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

